Mitochondria-Targeted Antioxidants as Promising Drugs for Treatment of Age-Related Brain Diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Much experimental evidence suggests that age-related brain pathologies are most often mediated by reactive oxygen species primarily originating from mitochondria (mROS). Two papers with such evidence have been recently published in the Journal of Alzheimer's Disease (Stefanova et al., J Alzheimers Dis 21, 476-491, 2010; Lloret et al., J Alzheimers Dis, doi: 10.3233/JAD-2011-110890). In the first paper, it was shown that appearance of a typical behavioral trait of aging in rats (that old animals do not enter an open arm in a maze) was completely reversed by ten weeks treatment of the old rats with the mitochondria-targeted antioxidant SkQ1. In the second article, the authors identified molecular mechanisms by which amyloid-β-induced mROS can mediate hyperphosphorylation of the tau protein, a key event in Alzheimer's disease. Conventional antioxidants prevented such hyperphosphorylation. In this article, I will summarize the present state of the art in this field. I conclude that mitochondria-targeted rechargeable antioxidants are promising as tools to treat brain pathologies developing in elderly humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“memory accompanying AD [17–19].”
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Long-Term Potentiation--A Decade of Progress?
Malenka, R. C., & Nicoll, A. R. A. (1999) · Science · doi:10.1126/science.285.5435.1870 · Cited by 2,729
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173 · cited 1×
“Just this property of MitoQ introduced by Murphy and Smith before SkQs were tested [24] might be the reason why clinical trials of MitoQ were without positive results in the case of Parkinson’s disease [24, 25] and Friedrich’s ataxia [26].”
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics
Butterfield, D. A., Perluigi, M., & Sultana, R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.026 · Cited by 363
Amyloid‐Beta Interaction with Mitochondria
Pagani, L., & Eckert, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/925050 · Cited by 309
V. Skulachev, M., N. Antonenko, Y., N. Anisimov, V., V. Chernyak, B., A. Cherepanov, D., A. Chistyakov, V., V. Egorov, M., G. Kolosova, N., A. Korshunova, G., G. Lyamzaev, K., et al. (2011) · Current Drug Targets · doi:10.2174/138945011795528859 · Cited by 156
Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation
Lott, I. T., Doran, E., Nguyen, V. Q., Tournay, A., Head, E., & Gillen, D. L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34114 · Cited by 136 · cited 1×
“Notably, non-targeted antioxidants ( -tocopherol, ascorbate, and -lipoate) proved to be safe but ineffective in treating AD patients [47].”
Cited by
Free radicals, reactive oxygen species, oxidative stress and its classification
Lushchak, V. I. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.10.016 · Cited by 1,649
Contaminant-induced oxidative stress in fish: a mechanistic approach
Lushchak, V. I. (2016) · Fish Physiology and Biochemistry · doi:10.1007/s10695-015-0171-5 · Cited by 380
Manganese neurotoxicity and the role of reactive oxygen species
Martinez-Finley, E. J., Gavin, C. E., Aschner, M., & Gunter, T. E. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.032 · Cited by 332
Wang, Y., Chen, Y., Zhang, X., Lu, Y., & Chen, H. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104248 · Cited by 262
Reactive oxygen species: sources, consequences and targeted therapy in type 2 diabetes
Panigrahy, S. K., Bhatt, R., & Kumar, A. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1207650 · Cited by 103
Metadata
- Authors
- Skulachev, V. P.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-01-25
- Volume
- 28
- Issue
- 2
- Pages
- 283-289
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1493900409
- Cited by
- 105
- References
- 10
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.